Squamous cell carcinoma of the lung: improving the detection and management of immune-related adverse events.
Lara KujtanRama Krishna KanchaBeth GustafsonLindsey DouglassChristopher Rh WardBlake BuzardJanakiraman SubramanianPublished in: Expert review of anticancer therapy (2022)
IRAEs are unique compared to standard chemotherapy. As the role of ICIs expand across all stages of squamous cell NSCLC and with different combinations of antineoplastics, management of IRAEs will become crucial. Optimal management of IRAEs requires multidisciplinary teamwork. Further investigation into the pathophysiology of IRAEs can enhance current management strategies.